000			01957 a2200553 4500
005			20250518081248.0
264		0	_c20201118
008			202011s 0 0 eng d
022			_a1745-6215
024	7		_a10.1186/s13063-019-4000-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aMichielsens, Celia A J
245	0	0	_aDose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. _h[electronic resource]
260			_bTrials _cJan 2020
300			_a90 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial
650	0	4	_aAdalimumab _xadverse effects
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aArthritis, Psoriatic _xdrug therapy
650	0	4	_aBayes Theorem
650	0	4	_aCase-Control Studies
650	0	4	_aCost-Benefit Analysis
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aEtanercept _xadverse effects
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aInfliximab _xadverse effects
650	0	4	_aNetherlands _xepidemiology
650	0	4	_aQuality of Life
650	0	4	_aResearch Design
650	0	4	_aSeverity of Illness Index
650	0	4	_aSpondylarthritis _xdrug therapy
650	0	4	_aTumor Necrosis Factor Inhibitors _xadverse effects
650	0	4	_aYoung Adult
700	1		_aBoers, Nadine
700	1		_aden Broeder, Nathan
700	1		_aWenink, Mark H
700	1		_avan der Maas, Aatke
700	1		_aMahler, Elien A M
700	1		_aMulder, Michelle L M
700	1		_avan der Heijde, Désirée
700	1		_avan den Hoogen, Frank H J
700	1		_aVerhoef, Lise M
700	1		_aden Broeder, Alfons A
773	0		_tTrials _gvol. 21 _gno. 1 _gp. 90
856	4	0	_uhttps://doi.org/10.1186/s13063-019-4000-5 _zAvailable from publisher's website
999			_c30522388 _d30522388